Effect of 6-week tadalafil treatment on blood-based biomarkers of neurodegeneration: A post-hoc analysis of a randomized controlled trial - PubMed
3 hours ago
- #Alzheimer's disease
- #biomarkers
- #neurodegeneration
- Tadalafil, a PDE-5 inhibitor, was studied for its effects on neurodegeneration biomarkers in type 2 diabetes patients.
- The study was a post-hoc analysis of a randomized controlled trial involving 15 participants.
- Tadalafil reduced plasma amyloid-β 40 and 42 levels but did not affect the amyloid-β 42/40 ratio.
- Glial fibrillary acidic protein (GFAP) levels were reduced, but other biomarkers like phosphorylated tau217, neurofilament light protein, and growth/differentiation factor 15 remained unchanged.
- The findings suggest tadalafil may influence amyloid metabolism and astroglial activation in diabetes patients.
- Further clinical trials are needed to confirm these results.